
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Center for Health Services Research, Vanderbilt University, Nashville, Tennessee [S. M. B.]; Departments of Family and Preventive Medicine [R. M. B.] and Pathology [M. W.], School of Medicine, and Department of Epidemiology and Biostatistics, Norman J. Arnold School of Public Health [R. M. B., J. R. H.], University of South Carolina, Columbia, South Carolina; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland [K. A. M.]; Forsyth Medical Specialists, PA, Winston-Salem, North Carolina [M. F. F.]; Wake Forest University, Winston-Salem, North Carolina [W. M. R., K. R. G.]; and School of Public Health, University of Texas, Houston, Texas [A. C.]
Previous epidemiological studies have been inconclusive in demonstrating an inverse association among calcium, vitamin D, and risk for colorectal adenoma. The purpose of this analysis was to evaluate the associations among calcium and vitamin D and risk for incident, sporadic colorectal adenoma according to the vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug (NSAID) use. We analyzed data from a colonoscopy-based case-control study (n = 177 cases, 228 controls) conducted in North Carolina between 1995 and 1997. Adjusted odds ratios (ORs) comparing participants in the highest to those in the lowest tertiles of total calcium and vitamin D intakes were 0.64 [95% confidence interval (CI), 0.351.15], Ptrend = 0.14 and 0.69 (95% CI, 0.411.18), and Ptrend = 0.19, respectively. Adjusted ORs for those in the upper tertile of total calcium intake relative to those in the lower were 0.25 (95% CI, 0.080.80) among those who had a Bb genotype, 0.57 (95% CI, 0.181.82) among those who had a bb genotype, and 0.36 (95% CI, 0.150.85) among those who did not take NSAIDs. The ORs for the highest tertile of calcium intake was 0.05 (95% CI, 0.010.41), Ptrend < 0.01 among those who were Bb and did not take NSAIDs, and 0.16 (95% CI, 0.021.36), Ptrend = 0.47 among those who were bb and did not take NSAIDs. These data support the hypotheses that higher calcium intakes may decrease risk for colorectal neoplasms, and that such a relationship is more readily detectable among those who do not take NSAIDs, and may be strongest among those who have at least one vitamin D receptor BsmI b allele.
This article has been cited by other articles:
![]() |
A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sweeney, K. Curtin, M. A. Murtaugh, B. J. Caan, J. D. Potter, and M. L. Slattery Haplotype analysis of common vitamin d receptor variants and colon and rectal cancers. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 744 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Grau, J. A. Baron, E. L. Barry, R. S. Sandler, R. W. Haile, J. S. Mandel, and B. F. Cole Interaction of Calcium Supplementation and Nonsteroidal Anti-inflammatory Drugs and the Risk of Colorectal Adenomas Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2353 - 2358. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Gong, D. Xie, Z. Deng, R. M. Bostick, S. J. Muga, T. G. Hurley, and J. R. Hebert The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas Carcinogenesis, March 1, 2005; 26(3): 579 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakagawa, A. Kawaura, S. Kato, E. Takeda, and T. Okano 1{alpha},25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer Carcinogenesis, February 1, 2005; 26(2): 429 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Grau, J. A. Baron, R. S. Sandler, R. W. Haile, M. L. Beach, T. R. Church, and D. Heber Vitamin D, Calcium Supplementation, and Colorectal Adenomas: Results of a Randomized Trial J Natl Cancer Inst, December 3, 2003; 95(23): 1765 - 1771. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |